hotspot -WSS

hotspot

author：fashion 2025-09-29 16:35:09 - browse：54636

What does Covid-19 have in store for the winter? When are good data not good enough? And how many would-be Wegovys are there?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Helen Branswell joins us to discuss the state of the Covid-19 pandemic heading into the fall and the rollout of boosters shots aimed at the latest viral variants. We also discuss the latest news in the life sciences, including an IPO implosion, a debate at the FDA, and the ups and downs of a career in biotech.

For more on what we cover, here’s the latest on booster shots; here’s more on Covid-19 in 2023; here’s the news on Alnylam Pharmaceuticals; here’s more on 2Seventy Bio; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Supreme Court strikes down use of affirmative action

WSS

Medicare details structure of new drug price negotiation program

United colonoscopy coverage change 'may cost lives,' doctors say

How to save PrEP access — and even expand it

Biden's order seeks to regulate AI risk without stifling innovation

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

BioMarin wins approval for gene therapy to treat hemophilia A

leisure time

hotspot

knowledge

As demand for Covid shots wanes, Moderna seeks its next success

At least 13 dead in Texas as scorching temps continue

Continuity nursing helped my family in our darkest PICU moments

Why Sanofi got shellacked over its spinoff

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Cancer drug shortages should be causing more outrage

Affirmative action in medical school literally saved lives

Alkermes shareholders re

Cancer drug shortages should be causing more outrage

focus

Medtronic CEO on promising devices for diabetes, hypertension

Telehealth options flood the market as retailers push virtual care

Senate panel to vote on hospitals, PBMs, prisoner care

Why Sanofi got shellacked over its spinoff

Senate panel to vote on hospitals, PBMs, prisoner care

Testing for cancer recurrence creates a new limbo for patients

leisure time

focus

knowledge

explore